Atiprimod blocks STAT3 phosphorylation and induces apoptosis in multiple myeloma cells

[1]  Z. Estrov,et al.  Nuclear factor–κB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis , 2004 .

[2]  K. Vanderkerken,et al.  Specific roles for the PI3K and the MEK–ERK pathway in IGF-1-stimulated chemotaxis, VEGF secretion and proliferation of multiple myeloma cells: study in the 5T33MM model , 2004, British Journal of Cancer.

[3]  K. Anderson.  Stem cell transplantation for myeloma. , 2004, Current hematology reports.

[4]  K. Anderson.  Bortezomib therapy for myeloma. , 2004, Current hematology reports.

[5]  S. Colla,et al.  Downmodulation of ERK protein kinase activity inhibits VEGF secretion by human myeloma cells and myeloma-induced angiogenesis , 2004, Leukemia.

[6]  E. Dees,et al.  The proteasome as a target for cancer therapy. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  M. Dimopoulos,et al.  Treatment of plasma cell dyscrasias with thalidomide and its derivatives. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  A. Lichtenstein,et al.  Preferential killing of PTEN-null myelomas by PI3K inhibitors through Akt pathway , 2003, Oncogene.

[9]  J. Lis,et al.  PARP Goes Transcription , 2003, Cell.

[10]  Sujay K. Singh,et al.  Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor–κB and IκBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis , 2003 .

[11]  Alicia Samuels,et al.  Cancer Statistics, 2003 , 2003, CA: a cancer journal for clinicians.

[12]  Sujay K. Singh,et al.  Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. , 2003, Blood.

[13]  B. Dörken,et al.  In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp130/STAT3 pathway. , 2002, Blood.

[14]  S. Côté,et al.  Regulation of growth-related genes by interleukin-6 in murine myeloma cells. , 2002, Cytokine.

[15]  R. Orlowski,et al.  NF-?B as a therapeutic target in cancer , 2002 .

[16]  A. Ogata,et al.  Clinical significance of vascular endothelial growth factor and hepatocyte growth factor in multiple myeloma , 2002, British journal of haematology.

[17]  R. Orlowski,et al.  NF-kappaB as a therapeutic target in cancer. , 2002, Trends in molecular medicine.

[18]  S. Alkan,et al.  Analysis of expression of nuclear factor κB (NF‐κB) in multiple myeloma: downregulation of NF‐κB induces apoptosis , 2001 .

[19]  L. Pilarski,et al.  Expression of IL-6 and IL-6 receptors by circulating clonotypic B cells in multiple myeloma: potential for autocrine and paracrine networks. , 2001, Experimental hematology.

[20]  K. Anderson,et al.  Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration. , 2001, Blood.

[21]  T. Hirano,et al.  Roles of STAT3 in mediating the cell growth, differentiation and survival signals relayed through the IL-6 family of cytokine receptors , 2000, Oncogene.

[22]  Pinder,et al.  Apoptosis can be detected in attached colonic adenocarcinoma HT29 cells using annexin V binding, but not by TUNEL assay or sub-G0 DNA content , 2000, Cytometry.

[23]  A. Strasser,et al.  Apoptosis signaling. , 2000, Annual review of biochemistry.

[24]  B. Aggarwal,et al.  Assay for redox-sensitive transcription factor. , 2000, Methods in enzymology.

[25]  R. Clarke,et al.  Apoptosis can be detected in attached colonic adenocarcinoma HT29 cells using annexin V binding, but not by TUNEL assay or sub-G0 DNA content. , 2000, Cytometry.

[26]  R. Bataille,et al.  IL‐6 up‐regulates Mcl‐1 in human myeloma cells through JAK / STAT rather than Ras / MAP kinase pathway , 1999, European journal of immunology.

[27]  D. Nicholson,et al.  Caspase structure, proteolytic substrates, and function during apoptotic cell death , 1999, Cell Death and Differentiation.

[28]  E. Estey,et al.  Phenylarsine oxide blocks interleukin-1beta-induced activation of the nuclear transcription factor NF-kappaB, inhibits proliferation, and induces apoptosis of acute myelogenous leukemia cells. , 1999, Blood.

[29]  K. Anderson,et al.  Advances in the biology of multiple myeloma: therapeutic applications. , 1999, Seminars in oncology.

[30]  B. Barlogie,et al.  Role of NF-kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced apoptosis by bcl-2. , 1999, Blood.

[31]  J. Turkson,et al.  Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. , 1999, Immunity.

[32]  J A Steinkamp,et al.  Apoptosis induced with different cycle-perturbing agents produces differential changes in the fluorescence lifetime of DNA-bound ethidium bromide. , 1998, Cytometry.

[33]  Allard Kaptein,et al.  Dominant Negative Stat3 Mutant Inhibits Interleukin-6-induced Jak-STAT Signal Transduction (*) , 1996, The Journal of Biological Chemistry.

[34]  S. Sarkar,et al.  Disease-modifying activity of SK&F 106615 in rat adjuvant-induced arthritis. Multiparameter analysis of disease magnetic resonance imaging and bone mineral density measurements. , 1996, Arthritis and rheumatism.

[35]  T. Libermann,et al.  Multiple myeloma cell adhesion-induced interleukin-6 expression in bone marrow stromal cells involves activation of NF-kappa B. , 1996, Blood.

[36]  C Haanen,et al.  A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. , 1995, Journal of immunological methods.

[37]  R. Jove,et al.  Enhanced DNA-binding activity of a Stat3-related protein in cells transformed by the Src oncoprotein. , 1995, Science.

[38]  A. Lichtenstein,et al.  Interleukin-6 inhibits apoptosis of malignant plasma cells. , 1995, Cellular immunology.

[39]  B. Klein,et al.  Interleukin-6 in human multiple myeloma. , 1995, Blood.

[40]  P. Griffin,et al.  Inactivation of interleukin-1 beta converting enzyme by peptide (acyloxy)methyl ketones. , 1994, Biochemistry.

[41]  Z. Estrov,et al.  Persistence of self-renewing leukemia cell progenitors during remission in children with B-precursor acute lymphoblastic leukemia. , 1994, Leukemia.

[42]  J. Kupiec-Weglinski,et al.  INDUCTION OF NONSPECIFIC X‐IRRADIATION‐RESISTANT SUPPRESSOR CELL ACTIVITY IN VIVO AND PROLONGATION OF VASCULARIZED ALLOGRAFT SURVIVAL BY SK&F 105685, A NOVEL IMMUNOMODULATORY AZASPIRANE , 1993, Transplantation.

[43]  A. Badger,et al.  The azaspirane SKF 105685 ameliorates renal allograft rejection in rats. , 1993, Journal of the American Society of Nephrology : JASN.

[44]  A. Badger,et al.  Prevention of diabetes and induction of non-specific suppressor cell activity in the BB rat by an immunomodulatory azaspirane, SK&F 106610. , 1993, Journal of autoimmunity.

[45]  L. Larsson,et al.  Expression of the bcl-2 gene in human multiple myeloma cell lines and normal plasma cells. , 1992, Blood.

[46]  A. Badger,et al.  Antiarthritic and Suppressor Cell Inducing Activity of Azaspiranes: Structure‐Function Relationships of a Novel Class of Immunomodulatory Agents. , 1991 .

[47]  J. Kupiec-Weglinski,et al.  SK&F 105685: a novel immunosuppressive compound with efficacy in animal models of autoimmunity and transplantation. , 1991, Transplantation proceedings.

[48]  J. Talmadge,et al.  Induction of non-specific suppressor cells and myeloregulatory effects of an immunomodulatory azaspirane, SK&F 105685. , 1991, International journal of immunopharmacology.

[49]  A. Badger,et al.  Antiarthritic and suppressor cell inducing activity of azaspiranes: structure-function relationships of a novel class of immunomodulatory agents. , 1990, Journal of medicinal chemistry.

[50]  J. Norton,et al.  Immunoglobulin heavy chain variable region family usage is independent of tumor cell phenotype in human B lineage leukemias , 1990, European journal of immunology.

[51]  A. Badger,et al.  Beneficial effects of long-term treatment with SK&F 105685 in murine lupus nephritis. , 1990, The Journal of pharmacology and experimental therapeutics.

[52]  J. Talmadge,et al.  Induction of non-specific suppressor cells in normal Lewis rats by a novel azaspirane SK&F 105685. , 1990, Journal of autoimmunity.

[53]  K. Mitomo,et al.  Involvement of a NF-kappa B-like transcription factor in the activation of the interleukin-6 gene by inflammatory lymphokines , 1990, Molecular and cellular biology.

[54]  C. Olive,et al.  A serum-free culture method for myeloma progenitors in vitro: proliferative and immunophenotypic characteristics. , 1990, Experimental hematology.

[55]  M. Jourdan,et al.  Interleukin-6 is a major myeloma cell growth factor in vitro and in vivo especially in patients with terminal disease. , 1990, Current topics in microbiology and immunology.

[56]  J. Talmadge,et al.  Inhibition of animal models of autoimmune disease and the induction of non-specific suppressor cells by SK&F 105685 and related azaspiranes. , 1989, International journal of immunopharmacology.

[57]  P. Selby,et al.  A simple method for culturing myeloma cells from human bone marrow aspirates and peripheral blood in vitro , 1988, British journal of haematology.

[58]  H. Asaoku,et al.  Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas , 1988, Nature.

[59]  H. Handa,et al.  Generation of functional clonal cell lines from human bone marrow stroma. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[60]  J. Gershoni,et al.  Protein blotting: principles and applications. , 1983, Analytical biochemistry.

[61]  H. Towbin,et al.  Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. , 1979, Proceedings of the National Academy of Sciences of the United States of America.

[62]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.